On 09 November 2018
Strides Pharma Science announced that its subsidiary, Strides Pharma Global has entered into an exclusive product development, licensing and supply agreement with SUDA Pharmaceuticals for novel drug SUD-001H, an oral spray of sumatriptan to treat migraine headache for the US market. The company focuses presently on developing portfolio of complex and specialty products including products filed under the 505B (2) regulatory pathway. The partnership with SUDA is part of company's specialty portfolio buildout for the US market.Powered by Capital Market - Live News